Still two key updates due this quarter - not sure if they will even divulge when they have passed off the candidates under the $142M Genentech deal but I would assume yes ? The later should be the real rattler though with proprietary candidates put forward. Still get the niggly feeling a new deal is pending.
Genentech
"Several promising candidates have been identified during the screening process, which is expected to conclude by October, 2015. Genentech will then have up to 12 months to evaluate results before deciding whether to licence or extend its option over the peptides discovered from the collaboration. In either case Phylogica would be eligible to receive a significant milestone payment."
Oncology
"Initial screens identified hundreds of hits against each target. Subsequent efforts have focussed on filtering these hits through a series of functional assays to identify the most potent candidates. Lead hits are currently being expressed as proteins fused to a cell penetrating Phylomer and then tested for activity when delivered as drugs into various cancer cell lines. The overall goal is to identify proprietary leads that function with equivalent or greater potency than Omomyc. Results from these studies will be reported early Q4 2015."
(20min delay)